Advertisement

Cefazolin Injection

[06 May 2013]

Products Affected - Description

Cefazolin injection, BBraun
2 gram/50 mL premix (NDC 00264-3105-11)

Cefazolin injection, Apotex
1 gram, 10 count (NDC 60505-0749-04) - discontinued

Cefazolin injection, Hospira
1 gram, 25 count (NDC 00409-0805-01)

 
Cefazolin injection, Sagent
500 mg, 25 count (NDC 25021-0100-10)

Reason for the Shortage

  • BBraun and Sagent have cefazolin on shortage due to increased demand.
  • Hospira and Sandoz had cefazolin on shortage due to manufacturing delays.

Available Products

Cefazolin injection, APP
500 mg, 1 count (NDC 63323-0236-10)
1 gram, 25 count (NDC 63323-0237-10)
10 gram, 1 count (NDC 63323-0238-61)
20 gram, 1 count (NDC 63323-0446-66)

Cefazolin injection, Apotex
1 gram, 25 count (NDC 60505-0749-05)
1 gram, 25 count, Novaplus vials (NDC 60505-6093-05)
10 gram, 1 count (NDC 60505-0769-00)
10 gram, 1 count, Novaplus vials (NDC 60505-6094-00)

Cefazolin injection, BBraun
1 gram/50 mL premix (NDC 00264-3103-11)
 
Cefazolin injection, Hospira
1 gram, Add-Vantage vial, 25 count (NDC 00409-2585-01)
10 gram, 10 count (NDC 00409-0806-01)

Cefazolin injection, Sandoz
500 mg, 10 count (NDC 00781-3450-95)
500 mg, 10 count, Novaplus (NDC 00781-9338-95)
1 gram, 25 count (NDC 00781-3451-96)
10 gram, 10 count (NDC 00781-3452-95)

Cefazolin injection, Sagent
1 gram, 25 count (NDC 25021-0101-10)
10 gram, 1 count (NDC 25021-0102-99)

Cefazolin injection, West-Ward
500 mg, 25 count (NDC 00143-9923-90)
1 gram, 25 count (NDC 00143-9924-90)
10 gram, 10 count (NDC 00143-9983-03)

Estimated Resupply Dates

  • BBraun has cefazolin 2 gram/50 mL premixes on allocation for customers with a direct order history.
  • Hospira has cefazolin 1 gram vials on back order and the company estimates a release date in May 2013.
  • Sagent has cefazolin 500 mg vials on allocation with an estimated release date of additional product in 2nd quarter, 2013.

Related Shortages

Updated

May 6, 2013; April 12, 2013; April 1, 2013; March 29, 2013; March 7, 2013; February 12, 2013; February 5, 2013; January 23, 2013; January 10, 2013, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity

Get the latest updates on ASHP's advocacy activity on drug shortages.



In Cooperation With

University of Utah & Novation
Advertisement